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We thank Drs Buschmann and Hossmann for their comments on our study. We are honored to have the opinions of the researchers who made such great contributions in deciphering the molecular mechanisms of "neovessel" biology. 1 In our recent study of stroke rats treated with granulocyte colony-stimulating factor (G-CSF), 2 we found that mobilized stem cells or endothelial progenitor cells (EPCs) labeled with BrdU contributed to "re-endothelialization and angiogenesis" in the perivascular area of the penumbric region of the brain. To further confirm this phenomenon, we conducted experiments to demonstrate that the proliferative marker ki67 3 was present in fluorescein isothiocyanate-dextran-perfused cerebral vessels of the penumbric region in the G-CSF-treated group (data not shown). These results suggested that mobilized EPCs contribute to "line-up" and "build" new vessels in the ischemic brain. We also found, however, that the EPCs incorporative rate for the construction of new blood vessels in the absence of brain ischemia was relatively low, which was because of the lack of upregulation of the chemoattractive power of stromal cell-derived factor-1 and its receptor CXC chemokine receptor 4. Furthermore, we conclude that the efficiency of neovascularization may not be solely attributable to the incorporation of EPCs but also may be influenced by the release of angiogenic substances, including vascular endothelial growth factor, surrounding the microenvironment of the ischemic brain.
We fully agree with Dr Buschmann and Dr Hossmann's opinion on the remodeling of the arterial wall-that collateral circulation may restore brain tissue perfusion in the ischemic brain. Nevertheless, based on our data, 2 it may be speculated that the power of both "old-fashioned" collaterals and "fancy" stem cells contributed to reconstruct the vascular network to improve the tissue perfusion. A previous study suggested, however, that the angiogenic formation of new capillaries in the penumbric region may be "nonfunctional" and does not improve the blood perfusion level of the ischemic brain. 4 To optimize therapeutic neovasculization, treatment strategies should therefore focus on strengthening re-endothelialization and remodeling of collateral circulation in ischemic tissue.
In conclusion, our studies suggest that the administration of exogenous G-CSF stimulates both angiogenesis and neurogenesis in the ischemic penumbric areas. Moreover, direct neuroprotection may reduce ischemic injury in the acute phase, whereas neurogenesis, angiogenesis, or both may contribute to longer-term repair of the injured brain.
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